Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Anat Rec (Hoboken). 2013 Dec;296(12):1857-64. doi: 10.1002/ar.22825. Epub 2013 Oct 28.

The effect and mechanism of CXCR4 silencing on metastasis suppression of human glioma U87 cell line.

Author information

  • 1Department of Clinical Laboratory, Tianjin Huan Hu Hospital, Tianjin, 300060, China; Tianjin Key Laboratory of Cerebral Vessels and Neural Degeneration, Tianjin, 300060, China.

Abstract

Tumor metastasis is the major cause of treatment failure and poor prognosis of glioma. Inhibiting metastasis has become an important therapeutic strategy for glioma treatment. CXCR4 has been proved to play an important role in the occurrence and development of tumors. In order to illustrate the effect of CXCR4 on glioma metastasis, we investigated the role of CXCR4 in U87 cells metastasis based on the CXCR4 silencing tumor cells. In this study, we found that CXCR4 silencing could suppress U87 cells invasion and adhesion potential, production of TGF-β1, IL-6, and IL-8, and blocked the G0/G1 phase of the cell cycle. We also found that CXCR4 silencing could up-regulate the mRNA and protein expression of p53, p21, and E-cadherin, and down-regulate the mRNA and protein expression of CD44 and MMP-2/-9. Meanwhile, CXCR4 silencing could decrease the phosphorylation of p-AKT and transcription activity of NF-κB promoter, and increased the phosphorylation of PTEN. The results provided a new research basis for the further study of CXCR4 gene, the screening of human glioma, as well as the target treatment for glioma and its prognosis.

Copyright © 2013 Wiley Periodicals, Inc.

KEYWORDS:

CXCR4; glioma; tumor metastasis

PMID:
24249397
[PubMed - indexed for MEDLINE]
Free full text

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk